Toggle light / dark theme

Short‐Term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States

How does the short-term care burden compare between heart transplants and LVADs? LVADs have higher upfront costs and longer stays; heart transplant recipients incur greater rehospitalization costs over time. @mogga72553 @HartfordHealthC


BackgroundHeart transplant (HT) and left ventricular assist devices (LVADs) are treatment options for advanced heart failure refractory to standard therapy. Historically, LVADs have been used as either destination therapy or a bridge to transplant. However, recent changes to the organ allocation system have deprioritized patients on LVADs as transplant recipients, leading to divisive views on the role of an LVAD. The comparative short‐term care burden with each modality remains unclear.

Single-cell multi-omic analyses highlight the essential role of NKX2.2-CLEC16A/endosomal pathway for human pancreatic differentiation and function

Chen et al. provide a comprehensive roadmap of the gene regulatory networks governing human pancreatic differentiation and identify the essential roles of the NKX2.2-CLEC16A/endosomal pathway axis for islet organogenesis. This study also highlights the expandable pancreatic progenitor (ePP)-islet system as a powerful platform for investigating cell fate decisions and disease modeling.

Anchoring a key immune molecule makes T cells hit harder

Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could help explain how immune responses become weakened in cancer and chronic infection and inform the design of more effective vaccines.

In a new study led by Professor Mike Dustin at the Kennedy Institute, and the team lead Dr. Alexander Leithner (now at the University of Salzburg, Austria), in collaboration with Audun Kvalvaag, at the Institute for Cancer Research at the University Hospital Oslo, examined how the physical presentation of a protein called ICAM-1 (Intercellular Adhesion Molecule 1) on a target cells affects the activation of T cells—the immune system’s cells responsible for identifying and eliminating infected or cancerous cells.

Published in the Proceedings of the National Academy of Sciences, their findings show that when ICAM-1 is locked in place, rather than free to move within the cell membrane, T cells show a stronger response and become more effective at killing target cells. The study provides new insight that could help design better immune strategies and may have implications for vaccine design, cancer immunotherapy and understanding immune evasion.

Popular Anti-Aging Supplement May Fuel Cancer Growth — Here’s Why

This actually offers some significant new insights for both cancer treatment research and the development of anti-aging therapies. 🧠

Read more👇


A group of natural compounds attracting attention for their anti-aging potential has a dark side.

New research shows how a family of chemicals called polyamines speeds up the growth of cancer cells. Led by a team from the Tokyo University of Science in Japan, the study offers some significant new insights for both cancer treatment research and the development of anti-aging therapies.

Polyamines are essential molecules found in all living cells. Including compounds with colorful names like spermidine and putrescine, they regulate processes involving cell growth and protein synthesis.

Patient Safety Begins With Access: Safety Events That Occur Before Meeting the Patient

💬 Viewpoint by Victor Hassid, MD, MBA, and Haytham Kaafarani, MD, MPH: Administrative delays and access failures introduce patient safety risks but are rarely treated as safety events in health systems.


More than 2 decades after To Err Is Human,1 health care has made substantial progress in defining, measuring, and mitigating clinical harm—by adopting high-reliability principles, implementing safety reporting systems, standardizing protocols, and embedding accountability instead of blame into clinical workflows. Yet access to care—despite being the gateway to all downstream clinical activity—remains largely outside this safety framework.

Delays in access are often discussed as throughput problems, capacity constraints, or scheduling inefficiencies. Rarely are they framed as patient safety issues. This distinction is consequential. When access failures are viewed as operational challenges, they are addressed as desk tasks—episodically and locally. When they are viewed as safety failures, they require immediate systematic analysis, leadership attention, and organizational accountability.

High-reliability organization principles provide a useful lens for reframing patient access to care as safety, even when accountability spans multiple stakeholders rather than a single organization.2 The preoccupation of high-reliability organization with failure requires attention to near misses, not just catastrophic outcomes. Reluctance to simplify acknowledges that access pathways are complex sociotechnical systems, not simplistic linear workflows. Sensitivity to operations requires understanding how delays in record retrieval, insurance authorization, or appointment scheduling propagate through the system and translate into patient harm. Deference to expertise elevates the voices of frontline access staff who understand when and where systems break down. Commitment to resilience requires learning from access failures and rapidly redesigning processes to prevent recurrence.

High‐Throughput In Vivo Subcellular Analysis of Gold Nanoparticles for Tumor Mitochondrial Targeting

A DNA barcoding system enables high-throughput in vivo screening of mitochondrial-targeting gold nanoparticles. Thirty nanoparticle types with varied shapes, sizes, and ligands are individually barco…

A new reagent makes living brains transparent for deeper, non-invasive imaging

Making a living brain transparent and watching its neurons fire without disturbing their function—sounds like science fiction, doesn’t it? Yet the solution may already exist within our own bodies. In a paper published in Nature Methods, a research team led by Kyushu University introduces a new reagent called SeeDB-Live.

SeeDB-Live uses albumin—a common protein in blood serum—to clear tissue while preserving cellular function. The technique allows scientists to see deeper, brighter structures in both brain slices in a dish and living mice, achieving neural activity that was previously out of sight.

“This is the first time tissue clearing has been achieved without altering its biology,” says Takeshi Imai, professor at Kyushu University’s Faculty of Medical Sciences and the study’s senior author.

Diltiazem With Blood Thinners Tied to Bleeding Risk

Among patients with atrial fibrillation (AF) who initiated apixaban or rivaroxaban, the use of diltiazem was associated with a higher risk for serious bleeding complications than the use of metoprolol. The risk for bleeding was particularly elevated in patients who received diltiazem doses exceeding 120 mg daily.


Patients with atrial fibrillation who use diltiazem combined with apixaban or rivaroxaban face an increased risk for serious bleeding events compared with those who use metoprolol.

/* */